File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Human embryonic stem cells: Genetic manipulation on the way to cardiac cell therapies

TitleHuman embryonic stem cells: Genetic manipulation on the way to cardiac cell therapies
Authors
KeywordsSpecies Index: Animalia
Issue Date2005
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/reprotox
Citation
Reproductive Toxicology, 2005, v. 20 n. 3, p. 377-391 How to Cite?
AbstractAlmost 7 years after their first derivation from human embryos, a pressing urgency to deliver the promises of therapies based on human embryonic stem cells (hESC) has arisen. Protocols have been developed to support long-term growth of undifferentiated cells and partially direct differentiation to specific cell lineages. The stage has almost been set for the next step: transplantation in animal models of human disease. Here, we review the state-of-the-art with respect to the transplantation of embryonic stem cell-derived heart cells in animals. One problem affecting progress in this area and functional analysis in vivo in general, is the availability of genetically marked hESC. There are only a few cell lines that express reporter genes ubiquitously, and none is associated with particular lineages; a major hurdle has been the resistance of hESC to established infection and chemical transfection methodologies to introduce ectopic genes. The methods that have been successful are reviewed. We also describe the processes for generating a new, genetically-modified hESC line that constitutively expresses GFP as well as some of its characteristics, including its ability to form cardiomyocytes with electrophysiological properties of ventricular-like cells. © 2005 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/91673
ISSN
2015 Impact Factor: 2.85
2015 SCImago Journal Rankings: 1.263
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMoore, JCen_HK
dc.contributor.authorVan Laake, LWen_HK
dc.contributor.authorBraam, SRen_HK
dc.contributor.authorXue, Ten_HK
dc.contributor.authorTsang, SYen_HK
dc.contributor.authorWard, Den_HK
dc.contributor.authorPassier, Ren_HK
dc.contributor.authorTertoolen, LLen_HK
dc.contributor.authorLi, RAen_HK
dc.contributor.authorMummery, CLen_HK
dc.date.accessioned2010-09-17T10:23:08Z-
dc.date.available2010-09-17T10:23:08Z-
dc.date.issued2005en_HK
dc.identifier.citationReproductive Toxicology, 2005, v. 20 n. 3, p. 377-391en_HK
dc.identifier.issn0890-6238en_HK
dc.identifier.urihttp://hdl.handle.net/10722/91673-
dc.description.abstractAlmost 7 years after their first derivation from human embryos, a pressing urgency to deliver the promises of therapies based on human embryonic stem cells (hESC) has arisen. Protocols have been developed to support long-term growth of undifferentiated cells and partially direct differentiation to specific cell lineages. The stage has almost been set for the next step: transplantation in animal models of human disease. Here, we review the state-of-the-art with respect to the transplantation of embryonic stem cell-derived heart cells in animals. One problem affecting progress in this area and functional analysis in vivo in general, is the availability of genetically marked hESC. There are only a few cell lines that express reporter genes ubiquitously, and none is associated with particular lineages; a major hurdle has been the resistance of hESC to established infection and chemical transfection methodologies to introduce ectopic genes. The methods that have been successful are reviewed. We also describe the processes for generating a new, genetically-modified hESC line that constitutively expresses GFP as well as some of its characteristics, including its ability to form cardiomyocytes with electrophysiological properties of ventricular-like cells. © 2005 Elsevier Inc. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/reprotoxen_HK
dc.relation.ispartofReproductive Toxicologyen_HK
dc.subjectSpecies Index: Animaliaen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshCell Lineen_HK
dc.subject.meshGene Therapyen_HK
dc.subject.meshHeart Diseases - genetics - surgeryen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMyocytes, Cardiac - cytology - physiology - transplantationen_HK
dc.subject.meshStem Cell Transplantationen_HK
dc.subject.meshTotipotent Stem Cells - cytology - physiologyen_HK
dc.titleHuman embryonic stem cells: Genetic manipulation on the way to cardiac cell therapiesen_HK
dc.typeArticleen_HK
dc.identifier.emailLi, RA:ronaldli@hkucc.hku.hken_HK
dc.identifier.authorityLi, RA=rp01352en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.reprotox.2005.04.012en_HK
dc.identifier.pmid15967632-
dc.identifier.scopuseid_2-s2.0-21744459254en_HK
dc.identifier.hkuros183062-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-21744459254&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume20en_HK
dc.identifier.issue3en_HK
dc.identifier.spage377en_HK
dc.identifier.epage391en_HK
dc.identifier.isiWOS:000230805200010-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridMoore, JC=35185459800en_HK
dc.identifier.scopusauthoridVan Laake, LW=9533995100en_HK
dc.identifier.scopusauthoridBraam, SR=8638133400en_HK
dc.identifier.scopusauthoridXue, T=7005064190en_HK
dc.identifier.scopusauthoridTsang, SY=7102255908en_HK
dc.identifier.scopusauthoridWard, D=8638133700en_HK
dc.identifier.scopusauthoridPassier, R=6601957556en_HK
dc.identifier.scopusauthoridTertoolen, LL=7003875511en_HK
dc.identifier.scopusauthoridLi, RA=7404724466en_HK
dc.identifier.scopusauthoridMummery, CL=13604608300en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats